Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir.

The experimental cytomegalovirus UL97 kinase inhibitor maribavir was used to treat 2 cases of infection in which viral mutations that conferred ganciclovir and foscarnet resistance had evolved sequentially. In one case, viral shedding was cleared without evidence of maribavir resistance in an isolate obtained after therapy. In the other case, a high-grade viremia was initially reduced 50-fold but rebounded 2 months later, coincident with the emergence of viral UL97 mutations T409M and H411Y, which confer maribavir resistance. The relatively rapid onset of maribavir resistance probably resulted from incomplete viral suppression in an immunosuppressed host with a high viral load.
AuthorsLynne Strasfeld, Ingi Lee, Walter Tatarowicz, Stephen Villano, Sunwen Chou
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 202 Issue 1 Pg. 104-8 (Jul 1 2010) ISSN: 1537-6613 [Electronic] United States
PMID20504236 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antiviral Agents
  • Benzimidazoles
  • Ribonucleosides
  • maribavir
  • Adult
  • Aged
  • Antiviral Agents (therapeutic use)
  • Benzimidazoles (therapeutic use)
  • Cytomegalovirus (drug effects, genetics)
  • Cytomegalovirus Infections (transmission, virology)
  • Female
  • Heart Transplantation (adverse effects)
  • Humans
  • Lung Transplantation (adverse effects)
  • Male
  • Mutation
  • Ribonucleosides (therapeutic use)
  • Viral Load
  • Viremia

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: